Mycrodose Therapeutics is a pharmaceutical company that uses psychedelic APIs to treat brain and behavioural issues to produce better medicine delivery systems. Their delayed-dosing technology employs a unique, delayed microdosing strategy.
Mycrodose
Mycrodose is developing a transdermal psilocybin delivery system for Fragile X Syndrome, Obesity and Autisme Spectrum Disorder. Additionally, the company has sustained-release ketamine lozenges in their pipeline.
In September 2021, Mycrodose completed a Seed round of funding raising an undisclosed amount. Ambria Capital and Empath Ventures are to known investors.
Activities
B2B
B2C
Pharmaceutical
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates